January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven capabilities and personalised medicine platform from target identification through patient selection Research focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive PARIS & OXFORD, England & BOSTON-- Sanofi and Exscientia announced today a groundbreaking research Read more at the source #DrGPCR #GPCR #IndustryNews

., Tectonic ’s SVP, Head of Research. Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers. "General Eligibility Researchers affiliated to any legal entity in Ukraine (for example, schools and universities, research centers, governmental institutions, or private companies) Deadlines Start of the The purpose of the STSM is to carry out a collaborative research project on topics relevant to the network Read more at the source #DrGPCR #GPCR #IndustryNews

modulation-based drug discovery and development, announced today that it will issue its full-year 2021 financial results Tim Dyer , CEO, Roger Mills , CMO and Robert Lütjens , Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day. " Read more at the source #DrGPCR #GPCR

November 2 - 4: Get ready for the upcoming GPCR Retreat! signal transduction NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 Appoints Dieter Weinand, Former CEO Of Bayer Pharmaceuticals, As Independent Chairman Addex Adx71149 Phase 2 production to candidate validation October 25 - 27, 2023 | 3rd Annual Meeting IRN I-GPCRNet November 2 May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2

March 2022 "March 3, 2022 Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD Two School of Medicine faculty members — Susanna Naggie, MD , and Sudarshan Rajagopal, MD, PhD — have been elected to the Naggie and Rajagopal are two of 95 new members elected to the society for 2022. " Read more at the source #DrGPCR #GPCR #IndustryNews

Hi there readers! salt challenge in the Dahl SS rat GPCRs in Neuroscience Neurokinin-2 receptor negatively modulates substance Nordisk Invests 42 Billion Danish Kroner in New Manufacturing Facilities Addex ADX71149 Epilepsy Phase 2 May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2 - 7, 2024 | Chemotactic Cytokines October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry July 12 - 17

December 2021 "Drug development is rarely trivial. The sheer complexity of the cell and the astonishing diversity of diseases are just two reasons why researchers typically require years to uncover the mechanisms of disease before they can even dare to contemplate the development of therapeutic options and begin the long, arduous road to the clinic. Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links Registration closing dates: 6th September – registration against invoice (bank transfers): Tuesday, 6th September 30th September – online registration (card payments)" Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "The atypical chemokine receptor 1 (ACKR1) was discovered on erythrocytes as the Duffy blood group antigen ( Cutbush et al., 1950 ), also called Duffy-antigen/receptor for chemokines, or DARC ( Novitzky-Basso and Rot, 2012 ). The reported ACKR1 expression by macrophages in Hur et al. relied on using commercial anti-ACKR1 antibody investigate the specificity of FAB6695 and scrutinize the apparent ACKR1 expression in BM macrophages" Read

commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended June 30, 2022 and provided an overview of its recent Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for US $900,000) of additional research funding. The reserved indications, where Addex retains exclusive rights to develop its own independent GABAB PAM program, have also been expanded to include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain. " Read more at the

August 2022 RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. Sir or Madam, dear Colleagues, It gives me great pleasure to announce the fourth hybrid symposium on regulatory autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. Recently, functional autoantibodies targeting GPCRs have been associated with various disease-specific Read more at the source #DrGPCR #GPCR #IndustryNews

C-X-C motif chemokine ligand 12 (CXCL12) has two receptors: C-X-C chemokine motif receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3). β -arrestin to the receptor. , revealing a key role for the deeper binding pocket composed of residues in the transmembrane domains Read more at the source #DrGPCR #GPCR #IndustryNews

The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. for arrestin-2 and -3 translocation to the cannabinoid CB1 receptor and the consequences on G protein in Complex with CGRP and Gs Protein Industry News Monash University retains its N° 2 global ranking May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2 Mediated Signaling Networks June 25 - 29, 2024 | FENS Forum 2024 October 2024 | Biologics US 2024 October 2

the primary messenger, (2) a transducer that requires GTP, and (3) an amplifier that generates large Eric R. Chemistry, R. S. of. Ye, R. D. Regulation of nuclear factor κB activation by G-protein-coupled receptors. R. B. & Irannejad, R.

’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics " Ross Bathgate Read more at the source #DrGPCR #GPCR #IndustryNews

"We recently hosted our annual Scientific Advisory Board (SAB) summit at our site within Granta Park. Read more at the source #DrGPCR #GPCR #IndustryNews

Each ADS represents six shares. exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read

(Nasdaq: CRNX), announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24 Read more at the source #DrGPCR #GPCR #IndustryNews

Save the dates: November 2 - 4: We're sponsoring the GPCR Retreat and would love to meet you there! Signaling β-Arrestin-dependent and -independent endosomal G protein activation by the vasopressin type 2 consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer GPCR Events, Meetings, and Webinars October 25 - 27, 2023 | 3rd Annual Meeting IRN I-GPCRNet November 2 May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2

thrilled to announce that our co-founder Margaux Duchamp has been selected as a 30 under 30 Europe Forbes ranking #ForbesUnder30 #ArcoScreen #sciences #EPFL" Read more at the source #DrGPCR #GPCR #IndustryNews

STRASBOURG, France & MONTREAL- Domain Therapeutics , a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology , announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, Read more at the source #DrGPCR #GPCR #IndustryNews

Hi GPCR lovers👋, Ready for exciting news in the GPCR world? Read them below! Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist. Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 (July 2 - 7, 2023). 3rd Annual Meeting IRN I-GPCRNet (October 25 - 27, 2023) NEW GPCR Retreat (November 2 - 4, 2023) GPCR Jobs NEW Associate Director / Director, Clinical Operations Postdoctoral Research

Team Registrations are also open!  You have until 5 pm EST tomorrow to register. The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. Binders, Drugs, and more Discovery and development of macrocyclic peptide modulators of the cannabinoid 2 May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2 Forum 2024 NEW July 8 - 10, 2024 | 4th IRN i-GPCRnet Annual October 2024 | Biologics US 2024 October 2

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.-- Design Pharmaceuticals , a company redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million, including Read more at the source #DrGPCR #GPCR #IndustryNews

Save the dates: November 2 - 4: We are excited to announce that we are sponsors of the GPCR Retreat and , to address innovation gap in cardiometabolic diseases GPCR Events, Meetings, and Webinars October 2 production to candidate validation October 25 - 27, 2023 | 3rd Annual Meeting IRN I-GPCRNet November 2 May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2 (level I or II) Research Fellow Research Technician II - Surgery Post-Doc Research Associate Research